New antiretroviral drugs: maraviroc, raltegravir, and etravirine.

GUIDELINE TITLE
New antiretroviral drugs: maraviroc, raltegravir, and etravirine.

BIBLIOGRAPHIC SOURCE(S)
New York State Department of Health. New antiretroviral drugs: maraviroc, raltegravir, and etravirine. New York (NY): New York State Department of Health; 2009 Dec. 6 p. [13 references]

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: New York State Department of Health. New antiretroviral drugs: maraviroc, raltegravir, and etravirine. New York (NY): New York State Department of Health; 2008 Apr. 4 p. [7 references]

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

August 27, 2009 - Intelence (etravirine): Tibotec Therapeutics and the U.S. Food and Drug Administration (FDA) notified healthcare professionals of revisions to the WARNINGS AND PRECAUTIONS section of the prescribing information for Intelence (etravirine).

open here to see the full-text:
New antiretroviral drugs: maraviroc, raltegravir, and etravirine.